SCYNEXIS (NASDAQ:SCYX) Share Price Crosses Below 200 Day Moving Average of $1.78

SCYNEXIS, Inc. (NASDAQ:SCYX)’s share price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.78 and traded as low as $1.39. SCYNEXIS shares last traded at $1.44, with a volume of 130,980 shares.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Cantor Fitzgerald restated an “overweight” rating on shares of SCYNEXIS in a research note on Monday, April 1st. StockNews.com lowered SCYNEXIS from a “buy” rating to a “hold” rating in a research note on Monday, March 18th.

SCYNEXIS Stock Up 2.5 %

The company has a debt-to-equity ratio of 0.17, a current ratio of 6.26 and a quick ratio of 6.26. The stock has a market capitalization of $54.36 million, a P/E ratio of 1.09 and a beta of 1.57. The firm has a 50 day moving average of $1.59 and a 200-day moving average of $1.78.

Institutional Investors Weigh In On SCYNEXIS

Several large investors have recently modified their holdings of the stock. Renaissance Technologies LLC grew its stake in shares of SCYNEXIS by 55.5% in the 1st quarter. Renaissance Technologies LLC now owns 17,100 shares of the company’s stock valued at $51,000 after purchasing an additional 6,100 shares during the period. Northern Trust Corp grew its stake in shares of SCYNEXIS by 12.7% in the 2nd quarter. Northern Trust Corp now owns 54,421 shares of the company’s stock valued at $161,000 after purchasing an additional 6,127 shares during the period. Citigroup Inc. bought a new stake in shares of SCYNEXIS in the 1st quarter valued at approximately $26,000. State Street Corp grew its stake in shares of SCYNEXIS by 9.3% in the 1st quarter. State Street Corp now owns 78,630 shares of the company’s stock valued at $307,000 after purchasing an additional 6,694 shares during the period. Finally, Chicago Partners Investment Group LLC grew its stake in shares of SCYNEXIS by 20.4% in the 1st quarter. Chicago Partners Investment Group LLC now owns 50,192 shares of the company’s stock valued at $106,000 after purchasing an additional 8,517 shares during the period. 54.37% of the stock is currently owned by institutional investors.

SCYNEXIS Company Profile

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.